84 related articles for article (PubMed ID: 12700464)
1. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein.
Vishnuvardhan D; Moltke LL; Richert C; Greenblatt DJ
AIDS; 2003 May; 17(7):1092-4. PubMed ID: 12700464
[TBL] [Abstract][Full Text] [Related]
2. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
3. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
[TBL] [Abstract][Full Text] [Related]
4. Effect of benzo[a]pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer.
Sugihara N; Toyama K; Michihara A; Akasaki K; Tsuji H; Furuno K
Toxicology; 2006 Jun; 223(1-2):156-65. PubMed ID: 16647797
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
Choo EF; Leake B; Wandel C; Imamura H; Wood AJ; Wilkinson GR; Kim RB
Drug Metab Dispos; 2000 Jun; 28(6):655-60. PubMed ID: 10820137
[TBL] [Abstract][Full Text] [Related]
6. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Tong L; Phan TK; Robinson KL; Babusis D; Strab R; Bhoopathy S; Hidalgo IJ; Rhodes GR; Ray AS
Antimicrob Agents Chemother; 2007 Oct; 51(10):3498-504. PubMed ID: 17664327
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.
Janneh O; Jones E; Chandler B; Owen A; Khoo SH
J Antimicrob Chemother; 2007 Nov; 60(5):987-93. PubMed ID: 17890284
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
[TBL] [Abstract][Full Text] [Related]
9. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
[TBL] [Abstract][Full Text] [Related]
10. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.
Storch CH; Theile D; Lindenmaier H; Haefeli WE; Weiss J
Biochem Pharmacol; 2007 May; 73(10):1573-81. PubMed ID: 17328866
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
13. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
14. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
Castagna A; Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Hoetelmans R; Nauwelaers D; Lazzarin A
Antivir Ther; 2004 Aug; 9(4):537-43. PubMed ID: 15456085
[TBL] [Abstract][Full Text] [Related]
15. Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp.
Wang XD; Meng MX; Gao LB; Liu T; Xu Q; Zeng S
Int J Pharm; 2009 Aug; 378(1-2):1-8. PubMed ID: 19465099
[TBL] [Abstract][Full Text] [Related]
16. Effects of capsaicin on P-gp function and expression in Caco-2 cells.
Han Y; Tan TM; Lim LY
Biochem Pharmacol; 2006 Jun; 71(12):1727-34. PubMed ID: 16674925
[TBL] [Abstract][Full Text] [Related]
17. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
[TBL] [Abstract][Full Text] [Related]
18. Effect of p-glycoprotein inhibitor combinations on drug efflux from rat brain microvessel endothelial cells.
Yang ZY; Liu GQ
Pharmazie; 2004 Dec; 59(12):952-6. PubMed ID: 15638085
[TBL] [Abstract][Full Text] [Related]
19. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; Devane CL
J Pharmacol Exp Ther; 2006 May; 317(2):850-7. PubMed ID: 16439618
[TBL] [Abstract][Full Text] [Related]
20. Expression levels of human P-glycoprotein in in vitro cell lines: correlation between mRNA and protein levels for P-glycoprotein expressed in cells.
Shirasaka Y; Konishi R; Funami N; Kadowaki Y; Nagai Y; Sakaeda T; Yamashita S
Biopharm Drug Dispos; 2009 Apr; 30(3):149-52. PubMed ID: 19243013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
